2025-522431-34-00Not yet recruitingPhase 2
Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer
TAILOR-PANC: Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer (DPCG-02)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 18 May 2026
Brief summary (registry, in English)
To compare the efficacy of molecularly tailored therapy versus standard of care in patients with pancreatic cancer with actionable reimbursed druggable molecular alterations as measured by progression-free survival
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 1200 (estimated)
- First submitted
- 4 Mar 2026
- Start date
- 1 Oct 2026
- Lead sponsor
- Region Hovedstaden
- Diseases
- Pancreatic cancer
- EU CT number
- 2025-522431-34-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 1200
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced pancreatic cancer that has grown during or after chemotherapy and who have a molecular test report with treatment options.
- Age
- 18 years and over
- Sex
- All sexes
- Disease stage
- Pancreatic cancer confirmed by cytology or histology; advanced disease. ECOG performance status 0-2.
- Earlier treatment
- Must have had 1 line of chemotherapy for advanced disease (gemcitabine or 5-FU based) and progressed during or after it, or progressed within one year of adjuvant/neoadjuvant treatment.
- Biomarker or test result
- A personalized report with molecular testing results and detailed treatment options must be available.
Main reasons for not taking part
- Any serious or uncontrolled medical disorder that could add risk or affect the study results
- History of allergy or hypersensitivity to the study drugs
- Women who can have children and are pregnant or breastfeeding
- Organ or bone marrow function outside the limits set in the record
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results
- Allergies and Adverse Drug Reaction - History of allergy to study drug components - Hypersensitivity to the active substances
Other
- WOCBP who are pregnant or breastfeeding
Who the study is looking for
- Adult patients (aged 18 and over)
- Pancreatic cancer confirmed by cytology or histology
- Written informed consent before any specific study procedures
- Available personalized report communicating the molecular testing results and detailed treatment options
- Participants must have received and progressed during or after 1 line of systemic chemotherapy in the advanced setting (gemcitabine or 5-FU based regimens) or within one year of the adjuvant/neoadjuvant treatment
- ECOG Performance Status 0-2
- Participants must have normal organ and marrow function as defined below: - Absolute neutrophil count ≥ 1.5 x 10⁹/L - Platelet count ≥ 75 x 10⁹/L - Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) - AST/ALT ≤ 5 x ULN - Serum creatinine ≤ 1.5 x ULN or CrCl ≥ 50 mL/min (using the Cockcroft-Gault formula)
- Women of childbearing potential (WOCBP) must use method(s) of contraception as indicated in the protocol
- Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Aalborg University Hospital | Aalborg | Denmark | Not yet recruiting |
| Region Midtjylland | Aarhus N | Denmark | Not yet recruiting |
| Region Hovedstaden | Herlev | Denmark | Not yet recruiting |
| Sygehus Lillebaelt - Vejle Sygehus | Vejle | Denmark | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.